Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-acting HIV Treatments: Study Design, Logistics, and Access.
Murdock NA, Alajaji NE, Schaefer R, Boone CA, Campo RE, Dore GJ, Gandhi M, Gorospe JR, Gulick RM, Hodder SL, Liu J, Rhee MS, Rooney JF, Vannappagari V, Wilkin T, Miller V. Murdock NA, et al. Among authors: rhee ms. Open Forum Infect Dis. 2024 Jun 15;11(7):ofae337. doi: 10.1093/ofid/ofae337. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 38983711 Free PMC article. Review.
Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.
Subramanian R, Tang J, Zheng J, Lu B, Wang K, Yant SR, Stepan GJ, Mulato A, Yu H, Schroeder S, Shaik N, Singh R, Wolckenhauer S, Chester A, Tse WC, Chiu A, Rhee M, Cihlar T, Rowe W, Smith BJ. Subramanian R, et al. Mol Pharm. 2023 Dec 4;20(12):6213-6225. doi: 10.1021/acs.molpharmaceut.3c00626. Epub 2023 Nov 2. Mol Pharm. 2023. PMID: 37917742 Free PMC article.
Pharmacokinetics, Disposition, and Biotransformation of [14C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion.
Weber E, Subramanian R, Rowe W, Graupe M, Ling J, Shen G, Begley R, Sager J, Wolckenhauer S, Rhee M, Palaparthy R, Singh R. Weber E, et al. Clin Pharmacokinet. 2024 Feb;63(2):241-253. doi: 10.1007/s40262-023-01328-1. Epub 2024 Jan 18. Clin Pharmacokinet. 2024. PMID: 38236562
Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial.
Ogbuagu O, Molina JM, Chetchotisakd P, Ramgopal MN, Sanchez W, Brunetta J, Castelli F, Crofoot GE, Hung CC, Ronot-Bregigeon S, Margot NA, Wang H, Dvory-Sobol H, Rhee MS, Segal-Maurer S. Ogbuagu O, et al. Among authors: rhee ms. Clin Infect Dis. 2024 Aug 29:ciae423. doi: 10.1093/cid/ciae423. Online ahead of print. Clin Infect Dis. 2024. PMID: 39206943
241 results